NCT03043391 · OUTCOME

Percentage of Participants Requiring Low-dose Bevacizumab or Steroid

Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children · Source last updated 2024-04-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percentage of participants
Interval / dispersion: Not reported
Time frame: 1 year

What was measured

The percentage of participants requiring low-dose bevcizumab or steroid due to an inflammatory reaction secondary to an immune response to lerapolturev treatment

Groups in this outcome

All Participants Treated

All participants received a single open-label infusion of lerapolturev

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
All Participants Treated	8

Reported measurements

Source class 1

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
All Participants Treated	50	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
50

denoms

counts
group Id
OG000
value
8
units
Participants

description

The percentage of participants requiring low-dose bevcizumab or steroid due to an inflammatory reaction secondary to an immune response to lerapolturev treatment

groups

description
All participants received a single open-label infusion of lerapolturev
id
OG000
title
All Participants Treated

param Type

NUMBER

reporting Status

POSTED

time Frame

1 year

title

Percentage of Participants Requiring Low-dose Bevacizumab or Steroid

type

PRIMARY

unit Of Measure

percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice